1e
19
1
49
2
2
18
1b
1d
18
31
82
1d
2 29
1d
25
Tara C Mitchell, MD
78
82
Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania
28
71
3
5f
Director of Clinical Research, Tara Miller Melanoma Center
79
Section Chief of Melanoma/Sarcoma, Division of Hematology/Oncology
11
Department: Medicine
4
1
b
1d
46
Contact information
4d
4
3
3
1d
4d
Division of Hematology Oncology
2e Perelman Center for Advanced Medicine
1f 3400 Civic Center Blvd.
3d South Pavilion, 10th Floor
Philadelphia, PA 19104
26
2e Perelman Center for Advanced Medicine
1f 3400 Civic Center Blvd.
3d South Pavilion, 10th Floor
Philadelphia, PA 19104
2e
Office: 215-662-7908
32 Fax: 215-662-4646
24
f
32 Fax: 215-662-4646
24
18
Publications
23 a
3
2
29
23 a
Links
b6 Search PubMed for articles
d
4
b
1f
b6 Search PubMed for articles
d
13
Education:
21 7 BA 19 (Anthropology) c
2c Columbia University, 2000.
21 7 MD c
3f New York University School of Medicine, 2004.
c
3
3
3
3
8d
Permanent link21 7 BA 19 (Anthropology) c
2c Columbia University, 2000.
21 7 MD c
3f New York University School of Medicine, 2004.
c
2 29
21
1e
1d
24
5e
1d Cutaneous malignancies
71
16 Immune therpay
18 Targeted therapy
16 Phase I trials
1b Combination therapy
21 Experimental therapeutics
13 Pharmacology
e 29
27
Description of Clinical Expertise
19 Melanoma1d Cutaneous malignancies
71
Description of Research Expertise
19 Melanoma16 Immune therpay
18 Targeted therapy
16 Phase I trials
1b Combination therapy
21 Experimental therapeutics
13 Pharmacology
e 29
23
227 Ribas A, Hamid O, Daud A, Hodi FS, Wolchok JD, Kefford R, Joshua AM, Patnaik A, Hwu WJ, Weber JS, Gangadhar TC, Hersey P, Dronca R, Joseph RW, Zarour H, Chmielowski B, Lawrence DP, Algazi A, Rizvi NA, Hoffner B, Mateus C, Gergich K, Lindia JA, Giannotti M, Li XN, Ebbinghaus S, Kang SP, Robert C: Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. JAMA 315(15): 1600-9, April 2016 Notes: Gangadhar is Dr. Mitchell's maiden name.
1b5 Shannan B, Chen Q, Watters A, Perego M, Krepler C, Thombre R, Li L, Rajan G, Peterson S, Gimotty PA, Wilson M, Nathanson KL, Gangadhar TC, Schuchter LM, Weeraratna AT, Herlyn M, Vultur A: Enhancing the evaluation of PI3K inhibitors through 3D melanoma models. Pigment cell & melanoma research 29(3): 317-28, May 2016 Notes: Gangadhar is Dr. Mitchell's maiden name.
256 Dizon DS, Krilov L, Cohen E, Gangadhar T, Ganz PA, Hensing TA, Hunger S, Krishnamurthi SS, Lassman AB, Markham MJ, Mayer E, Neuss M, Pal SK, Richardson LC, Schilsky R, Schwartz GK, Spriggs DR, Villalona-Calero MA, Villani G, Masters G: Clinical Cancer Advances 2016: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 34(9): 987-1011, Mar 20 2016 Notes: Gangadhar is Dr. Mitchell's maiden name.
2d1 Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, Hodi FS, Schachter J, Pavlick AC, Lewis KD, Cranmer LD, Blank CU, O'Day SJ, Ascierto PA, Salama AK, Margolin KA, Loquai C, Eigentler TK, Gangadhar TC, Carlino MS, Agarwala SS, Moschos SJ, Sosman JA, Goldinger SM, Shapira-Frommer R, Gonzalez R, Kirkwood JM, Wolchok JD, Eggermont A, Li XN, Zhou W, Zernhelt AM, Lis J, Ebbinghaus S, Kang SP, Daud A.: Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncology 16(8): 908-18, August 2015 Notes: Gangadhar is Dr. Mitchell's maiden name.
212 Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, Benci JL, Xu B, Dada H, Odorizzi PM, Herati RS, Mansfield KD, Patsch D, Amaravadi RK, Schuchter LM, Ishwaran H, Mick R, Pryma DA, Xu X, Feldman MD, Gangadhar TC, Hahn SM, Wherry EJ, Vonderheide RH, Minn AJ.: Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 520(7547): 373-7, April 2015 Notes: Gangadhar is Dr. Mitchell's maiden name.
109 Gangadhar TC, Schuchter LM: Broad Applicability of Nivolumab in Melanoma Regardless of BRAF Mutation Status. JAMA oncology 1(4): 427-8, Jul 2015 Notes: Gangadhar is Dr. Mitchell's maiden name.
1d7 Wang T, Xiao M, Ge Y, Krepler C, Belser E, Lopez-Coral A, Xu X, Zhang G, Azuma R, Liu Q, Liu R, Li L, Amaravadi RK, Xu W, Karakousis G, Gangadhar TC, Schuchter LM, Lieu M, Khare S, Halloran MB, Herlyn M, Kaufman RE: BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth. Clinical cancer research 21(7): 1652-64, April 2015 Notes: Gangadhar is Dr. Mitchell's maiden name.
256 Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, Weber JS, Joshua AM, Hwu WJ, Gangadhar TC, Patnaik A, Dronca R, Zarour H, Joseph RW, Boasberg P, Chmielowski B, Mateus C, Postow MA, Gergich K, Elassaiss-Schaap J, Li XN, Iannone R, Ebbinghaus SW, Kang SP, Daud A: Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 384(9948): 1109-17, September 2014 Notes: Gangadhar is Dr. Mitchell's maiden name.
217 Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, Dronca R, Gangadhar TC, Patnaik A, Zarour H, Joshua AM, Gergich K, Elassaiss-Schaap J, Algazi A, Mateus C, Boasberg P, Tumeh PC, Chmielowski B, Ebbinghaus SW, Li XN, Kang SP, Ribas A: Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. The New England Journal of Medicine 369(2): 134-44, July 2013 Notes: Gangadhar is Dr. Mitchell's maiden name.
2c
7
1d
1f
Selected Publications
1fd Hodi FS, Hwu WJ, Kefford R, Weber JS, Daud A, Hamid O, Patnaik A, Ribas A, Robert C, Gangadhar TC, Joshua AM, Hersey P, Dronca R, Joseph R, Hille D, Xue D, Li XN, Kang SP, Ebbinghaus S, Perrone A, Wolchok JD: Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab. Journal of Clinical Oncology 34(13): 1510-7, May 2016 Notes: Gangadhar is Dr. Mitchell's maiden name.227 Ribas A, Hamid O, Daud A, Hodi FS, Wolchok JD, Kefford R, Joshua AM, Patnaik A, Hwu WJ, Weber JS, Gangadhar TC, Hersey P, Dronca R, Joseph RW, Zarour H, Chmielowski B, Lawrence DP, Algazi A, Rizvi NA, Hoffner B, Mateus C, Gergich K, Lindia JA, Giannotti M, Li XN, Ebbinghaus S, Kang SP, Robert C: Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. JAMA 315(15): 1600-9, April 2016 Notes: Gangadhar is Dr. Mitchell's maiden name.
1b5 Shannan B, Chen Q, Watters A, Perego M, Krepler C, Thombre R, Li L, Rajan G, Peterson S, Gimotty PA, Wilson M, Nathanson KL, Gangadhar TC, Schuchter LM, Weeraratna AT, Herlyn M, Vultur A: Enhancing the evaluation of PI3K inhibitors through 3D melanoma models. Pigment cell & melanoma research 29(3): 317-28, May 2016 Notes: Gangadhar is Dr. Mitchell's maiden name.
256 Dizon DS, Krilov L, Cohen E, Gangadhar T, Ganz PA, Hensing TA, Hunger S, Krishnamurthi SS, Lassman AB, Markham MJ, Mayer E, Neuss M, Pal SK, Richardson LC, Schilsky R, Schwartz GK, Spriggs DR, Villalona-Calero MA, Villani G, Masters G: Clinical Cancer Advances 2016: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 34(9): 987-1011, Mar 20 2016 Notes: Gangadhar is Dr. Mitchell's maiden name.
2d1 Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, Hodi FS, Schachter J, Pavlick AC, Lewis KD, Cranmer LD, Blank CU, O'Day SJ, Ascierto PA, Salama AK, Margolin KA, Loquai C, Eigentler TK, Gangadhar TC, Carlino MS, Agarwala SS, Moschos SJ, Sosman JA, Goldinger SM, Shapira-Frommer R, Gonzalez R, Kirkwood JM, Wolchok JD, Eggermont A, Li XN, Zhou W, Zernhelt AM, Lis J, Ebbinghaus S, Kang SP, Daud A.: Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncology 16(8): 908-18, August 2015 Notes: Gangadhar is Dr. Mitchell's maiden name.
212 Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, Benci JL, Xu B, Dada H, Odorizzi PM, Herati RS, Mansfield KD, Patsch D, Amaravadi RK, Schuchter LM, Ishwaran H, Mick R, Pryma DA, Xu X, Feldman MD, Gangadhar TC, Hahn SM, Wherry EJ, Vonderheide RH, Minn AJ.: Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 520(7547): 373-7, April 2015 Notes: Gangadhar is Dr. Mitchell's maiden name.
109 Gangadhar TC, Schuchter LM: Broad Applicability of Nivolumab in Melanoma Regardless of BRAF Mutation Status. JAMA oncology 1(4): 427-8, Jul 2015 Notes: Gangadhar is Dr. Mitchell's maiden name.
1d7 Wang T, Xiao M, Ge Y, Krepler C, Belser E, Lopez-Coral A, Xu X, Zhang G, Azuma R, Liu Q, Liu R, Li L, Amaravadi RK, Xu W, Karakousis G, Gangadhar TC, Schuchter LM, Lieu M, Khare S, Halloran MB, Herlyn M, Kaufman RE: BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth. Clinical cancer research 21(7): 1652-64, April 2015 Notes: Gangadhar is Dr. Mitchell's maiden name.
256 Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, Weber JS, Joshua AM, Hwu WJ, Gangadhar TC, Patnaik A, Dronca R, Zarour H, Joseph RW, Boasberg P, Chmielowski B, Mateus C, Postow MA, Gergich K, Elassaiss-Schaap J, Li XN, Iannone R, Ebbinghaus SW, Kang SP, Daud A: Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 384(9948): 1109-17, September 2014 Notes: Gangadhar is Dr. Mitchell's maiden name.
217 Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, Dronca R, Gangadhar TC, Patnaik A, Zarour H, Joshua AM, Gergich K, Elassaiss-Schaap J, Algazi A, Mateus C, Boasberg P, Tumeh PC, Chmielowski B, Ebbinghaus SW, Li XN, Kang SP, Ribas A: Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. The New England Journal of Medicine 369(2): 134-44, July 2013 Notes: Gangadhar is Dr. Mitchell's maiden name.
2c